PDT and Pharmacia to negotiate licensing agreement for photodynamic drug SnET2.
Executive Summary
PDT AND PHARMACIA TO NEGOTIATE PHOTODYNAMIC THERAPY LICENSING AGREEMENT for PDT's lead product, tin ethyl etiopurpurin (SnET2), for "worldwide development...in the fields of oncology, urology and dermatology," Pharmacia announced. Pharmacia SpA, an Italian subsidiary of Stockholm-based Pharmacia AB, and PDT signed a "letter of intent to initiate negotiations" on May 17.